Glypican-3的血清检测与原发性肝癌诊断的研究进展  

Advances in the relationship between the detection of glypican-3 in serum and the diagnosis of primary hepatic carcinoma

作　　者：余娟平[1] 张琼[1] 徐伟文[1] 李明[1,2] 

机构地区：[1]南方医科大学生物技术学院,广东广州510515 [2]中山大学达安基因股份有限公司,广东广州510660

出　　处：《分子诊断与治疗杂志》2013年第3期189-193,共5页Journal of Molecular Diagnostics and Therapy

基　　金：国家863项目(2012AA020205);广东省产学研项目(2010B090400422)

摘　　要：磷脂酰肌醇蛋白多糖-3(glypican-3,GPC3)是继AFP之后发现的一个新的肝细胞癌标志物。随着对GPC3研究的不断深入,发现它不但在肝细胞癌组织中有表达而且在血清中同样有表达。GPC3对HCC诊断的敏感性和特异性较高,尤其在肿瘤发生的早期,具有极大的临床应用价值,为早期HCC的诊断带来了希望。Glypican-3（GPC3） was confirmed to be a novel tumor marker for hepatocellular carcinoma（HCC） besides alpha-fetoprotein（AFP）. With the constant deepening of GPC3 research, it was found not only in tissues of patients with HCC but also in the serum. In the diagnosis of HCC, there were higher sensitivity and specificity, especially in the early stage, which had great value in clinical application, and bring new hope for the diagnosis of HCC.

关 键 词：磷脂酰肌醇蛋白多糖-3 肝细胞癌 诊断 

分 类 号：R735.7[医药卫生—肿瘤]